TECLens – The Future of Vision Correction

The future of vision correction is here.

Introducing Non-Invasive Quantitative Corneal
Cross-Linking (qCXL™)
Technology

Using ultraviolet light to gently strengthen and reshape the cornea. Designed to address refractive errors, including the growing presbyopic population.

Johnson & Johnson Invests in Refractive Technology Start-up TECLens

At TECLens, we’re dedicated to restoring vision and improving quality of life for millions of people around the world.

Our innovative treatment utilizes proprietary quantitative corneal cross-linking (qCXL™) technology and the CXLens® device to gently strengthen and reshape the cornea, designed to redefine vision correction for refractive errors, including restoring near vision for those with presbyopia. The procedure aims to be a comfortable, non-invasive, in-office treatments.

TECLens is also exploring future applications for hyperopia, progressive myopia in children and low-order myopia in adults, and keratoconus, promising a brighter future for vision correction.

Learn more about our technology.

Our advanced technology uses personalized precision planning combined with real-time ultrasound monitoring and targeted UV light to gently strengthen the cornea and gently alter its shape to improve vision, offering an alternative solution compared to traditional vision correction procedures.

Meet our team.

Meet the talented individuals driving innovation at TECLens. Our management team and medical advisory board are dedicated to developing cutting-edge solutions for advancing eye care and helping people to see the world more clearly.

Explore our pipeline of comprehensive solutions.

Discover the exciting potential of qCXL™- a first-of-its-kind, non-invasive technology designed to redesign vision correction for refractive errors. We’re developing solutions to provide lifelong therapeutic and refractive care—addressing a range of eye conditions. Our approach is designed to deliver comprehensive vision health throughout life.

Promising Feedback from Eye
Care Professionals

“The CXLens device is easy to use and is well tolerated by patients. For the first time I have been able to perform corneal collagen cross-linking with minimal to no discomfort following the procedure, and yet have been able to see significant improvement in both visual and refractive outcomes while stabilizing patients’ corneal ectasia.”

Introducing Non-Invasive Quantitative Corneal Cross-Linking (qCXL™) Technology

Learn more about our technology.

Meet our team.

Explore our pipeline of comprehensive solutions.

Promising Feedback from Eye Care Professionals

Introducing Non-Invasive Quantitative Corneal
Cross-Linking (qCXL™)
Technology

Promising Feedback from Eye
Care Professionals